Citations

Clear

1526 citation(s) found for "Sun, C".

First-Year Results of the American Board of Anesthesiology’s Objective Structured Clinical Examination for Initial Certification
Lien, Cynthia A. , Wang, Ting , Isaak, Robert S. , Peterson-Layne, Cathleen, Harman, Ann E., Macario, Alex, Gaiser, Robert R., Culley, Deborah J. , Keegan, Mark T. , Cole, Daniel J. , Fahy, Brenda G. , Dainer, Rupa J., Warner, David O. , Zhou, Yan , Suresh, Santhanam , Rathmell, James P. , Sun, Huaping

Mayo Clinic

Anesthesia & Analgesia | July 31, 2020 | Volume: 131 | Issue: 5 | Pages: 1412-1418

10.1213/ane.0000000000005086 | PMID 33079864 Get It

In 2018, the American Board of Anesthesiology (ABA) became the first US medical specialty certifying board to incorporate an Objective Structured Clinical Examination (OSCE) into its initial certification examination system. Previously, the ABA’s staged examination system consisted of 2 written examinations (the BASIC and ADVANCED examinations) and the Standardized Oral Examination (SOE). The OSCE and the existing SOE are now 2 separate components of the APPLIED Examination. This report presents the results of the first-year OSCE administration. A total of 1410 candidates took both the OSCE and the SOE in 2018. Candidate performance approximated a normal distribution for both the OSCE and the SOE, and was not associated with the timing of the examination, including day of the week, morning versus afternoon session, and order of the OSCE and the SOE. Practice-based Learning and Improvement was the most difficult station, while Application of Ultrasonography was the least difficult. The correlation coefficient between SOE and OSCE scores was 0.35 ([95% confidence interval {CI}, 0.30–0.39]; P < .001). Scores for the written ADVANCED Examination were modestly correlated with scores for the SOE ( r = 0.29 [95% CI, 0.25–0.34]; P < .001) and the OSCE ( r = 0.15 [95% CI, 0.10–0.20]; P < .001). Most of the candidates who failed the SOE passed the OSCE, and most of the candidates who failed the OSCE passed the SOE. Of the 1410 candidates, 77 (5.5%) failed the OSCE, 155 (11.0%) failed the SOE, and 25 (1.8%) failed both. Thus, 207 (14.7%) failed at least 1 component of the APPLIED Examination. Adding an OSCE to a board certification examination system is feasible. Preliminary evidence indicates that the OSCE measures aspects of candidate abilities distinct from those measured by other examinations used for initial board certification.
ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling
Li, Bingjue, Zhu, Chaohong, Dong, Lihua , Xiang, Wenyu, Davidson, Alan J. , Feng, Shi , Wang, Yucheng , Shen, Xiujin , Weng, Chunhua , Teng, Lisha, Wang, Junwen , Chen, Jianghua , Jiang, Hong , Chen, Jianghua , Jiang, Hong , Wang, Junwen , Qin, Jing , Wang, Cuili , Zhu, Tingting, Englert, Christoph

Mayo Clinic

The Journal of Pathology | July 27, 2020 | Volume: 252 | Issue: 3 | Pages: 274-289

10.1002/path.5517 | PMID 32715474 Get It

AbstractDisturbed intrauterine development increases the risk of renal disease. Various studies have reported that Notch signalling plays a significant role in kidney development and kidney diseases. A disintegrin and metalloproteinase domain 10 (ADAM10), an upstream protease of the Notch pathway, is also reportedly involved in renal fibrosis. However, how ADAM10 interacts with the Notch pathway and causes renal fibrosis is not fully understood. In this study, using a prenatal chlorpyrifos (CPF) exposure mouse model, we investigated the role of the ADAM10/Notch axis in kidney development and fibrosis. We found that prenatal CPF‐exposure mice presented overexpression of Adam10, Notch1 and Notch2, and led to premature depletion of Six2+ nephron progenitors and ectopic formation of proximal tubules (PTs) in the embryonic kidney. These abnormal phenotypic changes persisted in mature kidneys due to the continuous activation of ADAM10/Notch and showed aggravated renal fibrosis in adults. Finally, both ADAM10 and NOTCH2 expression were positively correlated with the degree of renal interstitial fibrosis in IgA nephropathy patients, and increased ADAM10 expression was negatively correlated with decreased kidney function evaluated by serum creatinine, cystatin C, and estimated glomerular filtration rate. Regression analysis also indicated that ADAM10 expression was an independent risk factor for fibrosis in IgAN. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Feasibility and Reliability Testing of Manual Electronic Health Record Reviews as a Tool for Timely Identification of Diagnostic Error in Patients at Risk
Soleimani, Jalal , Pinevich, Yuliya , Barwise, Amelia , Huang, Chanyan , Dong, Yue , Pickering, Brian W. , Barwise, Amelia K, Barwise, Amelia K , Dong, Yue , Herasevich, Vitaly , Gajic, Ognjen

Mayo Clinic

Applied Clinical Informatics | July 15, 2020 | Volume: 11 | Issue: 03 | Pages: 474-482

10.1055/s-0040-1713750 | PMID 32668480 Get It

Abstract Background Although diagnostic error (DE) is a significant problem, it remains challenging for clinicians to identify it reliably and to recognize its contribution to the clinical trajectory of their patients. The purpose of this work was to evaluate the reliability of real-time electronic health record (EHR) reviews using a search strategy for the identification of DE as a contributor to the rapid response team (RRT) activation. Objectives Early and accurate recognition of critical illness is of paramount importance. The objective of this study was to test the feasibility and reliability of prospective, real-time EHR reviews as a means of identification of DE. Methods We conducted this prospective observational study in June 2019 and included consecutive adult patients experiencing their first RRT activation. An EHR search strategy and a standard operating procedure were refined based on the literature and expert clinician inputs. Two physician-investigators independently reviewed eligible patient EHRs for the evidence of DE within 24 hours after RRT activation. In cases of disagreement, a secondary review of the EHR using a taxonomy approach was applied. The reviewers categorized patient experience of DE as Yes/No/Uncertain. Results We reviewed 112 patient records. DE was identified in 15% of cases by both reviewers. Kappa agreement with the initial review was 0.23 and with the secondary review 0.65. No evidence of DE was detected in 60% of patients. In 25% of cases, the reviewers could not determine whether DE was present or absent. Conclusion EHR review is of limited value in the real-time identification of DE in hospitalized patients. Alternative approaches are needed for research and quality improvement efforts in this field.
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Mi, Xiaoli , North, Khrystyna , Binder, Moritz , Penson, Alexander , Knorr, Katherine , Haddadin, Michael , Liu, Bo , Pangallo, Joseph , Benbarche, Salima , Wiseman, Daniel H. , Tefferi, Ayalew , Patnaik, Mrinal M. , Bradley, Robert K. , Binder, Moritz , Wiseman, Daniel H , Taylor, Justin , Lasho, Terra L. , Halene, Stephanie , Liang, Yang , Abdel‐Wahab, Omar

Mayo Clinic

Blood | July 8, 2020 | Volume: 136 | Issue: 13 | Pages: 1477-1486

10.1182/blood.2020006868 | PMID 32640014 Get It

Abstract Large-scale sequencing studies of hematologic malignancies have revealed notable epistasis among high-frequency mutations. One of the most striking examples of epistasis occurs for mutations in RNA splicing factors. These lesions are among the most common alterations in myeloid neoplasms and generally occur in a mutually exclusive manner, a finding attributed to their synthetic lethal interactions and/or convergent effects. Curiously, however, patients with multiple-concomitant splicing factor mutations have been observed, challenging our understanding of one of the most common examples of epistasis in hematologic malignancies. In this study, we performed bulk and single-cell analyses of patients with myeloid malignancy who were harboring ≥2 splicing factor mutations, to understand the frequency and basis for the coexistence of these mutations. Although mutations in splicing factors were strongly mutually exclusive across 4231 patients (q &lt; .001), 0.85% harbored 2 concomitant bona fide splicing factor mutations, ∼50% of which were present in the same individual cells. However, the distribution of mutations in patients with double mutations deviated from that in those with single mutations, with selection against the most common alleles, SF3B1K700E and SRSF2P95H/L/R, and selection for less common alleles, such as SF3B1 non-K700E mutations, rare amino acid substitutions at SRSF2P95, and combined U2AF1S34/Q157 mutations. SF3B1 and SRSF2 alleles enriched in those with double-mutations had reduced effects on RNA splicing and/or binding compared with the most common alleles. Moreover, dual U2AF1 mutations occurred in cis with preservation of the wild-type allele. These data highlight allele-specific differences as critical in regulating the molecular effects of splicing factor mutations as well as their cooccurrences/exclusivities with one another.
Preliminary Assessment of Intravoxel Incoherent Motion Diffusion‐Weighted MRI (IVIM‐DWI) Metrics in Alzheimer's Disease
Bergamino, Maurizio , Nespodzany, Ashley , Baxter, Leslie C. , Burke, Anna , Caselli, Richard J., Sabbagh, Marwan N. , Walsh, Ryan R., Stokes, Ashley M. , Baxter, Leslie C. , Caselli, Richard J.

Mayo Clinic

Journal of Magnetic Resonance Imaging | July 4, 2020 | Volume: 52 | Issue: 6 | Pages: 1811-1826

10.1002/jmri.27272 | PMID 32621405 Get It

BackgroundAlzheimer's disease (AD) is a progressive neurodegenerative disease that affects aging populations. Current MRI techniques are often limited in their sensitivity to underlying neuropathological changes.PurposeTo characterize differences in voxel‐based morphometry (VBM), apparent diffusion coefficient (ADC), and intravoxel incoherent motion diffusion‐weighted imaging (IVIM‐DWI) metrics in aging populations. Additionally, to investigate the connection between cognitive assessments and neuroimaging metrics.Study TypeProspective/cross‐sectional.PopulationIn all, 49 subjects, including 13 with AD dementia, 12 with mild cognitive impairment (MCI), and 24 healthy controls (HC).Field Strength/Sequence3T/magnetization‐prepared rapid acquisition gradient echo (MP‐RAGE) and IVIM‐DWIAssessmentAll participants completed a cognitive screening battery prior to MRI. IVIM‐DWI maps (pure diffusion coefficient [D], pseudodiffusion coefficient [D*], and perfusion fraction [f]) were generated from a biexponential fit of diffusion MRI data. VBM was performed on the standard T1‐weighted MP‐RAGE structural images. Group‐wise templates were used to compare across groups.Statistical TestsAnalysis of covariance (ANCOVA) with gender and age as covariates (familywise error [FWE] corrected, post‐hoc comparisons using Bonferroni correction) for group comparisons. Partial‐η2 and Hedges' g were used for effect‐size analysis. Spearman's correlations (false discovery rate [FDR]‐corrected) for the relationship between cognitive scores and imaging.ResultsClusters of significant group‐wise differences were found mainly in the temporal lobe, hippocampus, and amygdala using all VBM and IVIM methods (P < 0.05 FWE). While VBM showed significant changes between MCI and AD groups and between HC and AD groups, no significant clusters were observed between HC and MCI using VBM. ADC and IVIM‐D demonstrated significant changes, at P < 0.05 FWE, between HC and MCI, notably in the amygdala and hippocampus. Several voxel‐based correlations were observed between neuroimaging metrics and cognitive tests within the cognitively impaired groups (P < 0.05 FDR).Data ConclusionThese findings suggest that IVIM‐DWI metrics may be earlier biomarkers for AD‐related changes than VBM. The use of these techniques may provide novel insight into subvoxel neurodegenerative processes.Level of Evidence2Technical Efficacy Stage2 J. MAGN. RESON. IMAGING 2020;52:1811–1826.
Effects of microbiome rare taxa filtering on statistical analysis
Cao, Quy , Sun, Xinxin , Rajesh, Karun, Chalasani, Naga , Gelow, Kayla, Katz, Barry P., Shah, Vijay H. , Smirnova, Ekaterina , Sanyal, Arun J.

Mayo Clinic

No container title available | July 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-34781/v1 Get It

Abstract Background: Accuracy of microbial community detection in 16S rRNA marker-gene and metagenomic studies suffers from contamination and sequencing errors that lead to either falsely identifying microbial taxa that were not in the sample or misclassifying the taxa of DNA fragment reads. Filtering is defined as removing taxa that are present in a small number of samples and have small counts in the samples where they are observed. This approach reduces extreme sparsity of microbiome data and has been shown to correctly remove contaminant taxa in cultured "mock" datasets, where the true taxa compositions are known. Although filtering is frequently used, careful evaluation of its effect on the data analysis and scientific conclusions remains unreported. Here, we assess the effect of filtering on the alpha and beta diversity estimation, as well as its impact on identifying taxa that discriminate between disease states. Results: The effect of filtering on microbiome data analysis is illustrated on four datasets: two mock quality control datasets where same cultured samples with known microbial composition are processed at different labs and two disease study datasets. Results show that in microbiome quality control datasets, filtering reduces the magnitude of differences in alpha diversity and alleviates technical variability between labs, while preserving between samples similarity (beta diversity). In the disease study datasets, DESeq2 and linear discriminant analysis Effect Size (LEfSe) methods were used to identify taxa that are differentially expressed across groups of samples, and random forest models to rank features with largest contribution towards disease classiffcation. Results reveal that filtering retains significant taxa and preserves the model classification ability measured by the area under the receiver operating characteristic curve (AUC). The comparison between filtering and contaminant removal method shows that they have complementary effects and are advised to be used in conjunction. Conclusions: Filtering reduces the complexity of microbiome data, while preserving their integrity in downstream analysis. This leads to mitigation of the classification methods' sensitivity and reduction of technical variability, allowing researchers to generate more reproducible and comparable results in microbiome data analysis.
Mucosal impedance for esophageal disease: evaluating the evidence
Clarke, John O. , Ahuja, Nitin K. , Chan, Walter W. , Gyawali, C. Prakash , Horsley‐Silva, Jennifer L. , Kamal, A. N. , Vela, Marcelo F. , Xiao, Yinglian , Clarke, J , Gyawali, C P , Chan, Walter , Kamal, Afrin N.

Mayo Clinic

Annals of the New York Academy of Sciences | June 26, 2020 | Volume: 1481 | Issue: 1 | Pages: 247-257

10.1111/nyas.14414 | PMID 32588457 Get It

AbstractImpedance has traditionally been employed in esophageal disease as a means to assess bolus flow and reflux episodes. Recent and ongoing research has provided new and novel applications for this technology. Measurement of esophageal mucosal impedance, via either multichannel intraluminal impedance catheters or specially designed endoscopically deployed impedance catheters, provides a marker of mucosal integrity. Mucosal impedance has been shown to segregate gastroesophageal reflux disease (GERD) and eosinophilic esophagitis from non‐GERD controls and may play a role in predicting response to reflux intervention. More data are needed with regard to other esophageal subgroups, outcome studies, and functional disease. Our paper reviews the history of impedance in esophageal disease, the means of assessing baseline and mucosal impedance, data with regard to the newly developed mucosal impedance probes, the clinical utility of mucosal impedance in specific clinical conditions, and limitations in our existing knowledge, along with suggestions for future studies.
“It ain't over … till it's over!” Risk‐mitigation strategies for patients with gastrointestinal diseases in the aftermath of the COVID‐19 pandemic
Holtmann, Gerald , Camilleri, Michael , Tan, Victoria PY, Gwee, Kok‐Ann , Sugano, Kentaro , Sollano, Jose D. , Fock, Kwong Ming , Ghoshal, Uday C. , Chen, Minhu , Cohen, Henry , Ghoshal, Uday C , Holtmann, Gerald J , Quigley, Eamonn M.M. , Shah, Ayesha , Dignass, Axel

Mayo Clinic

Journal of Gastroenterology and Hepatology | June 8, 2020 | Volume: 35 | Issue: 7 | Pages: 1117-1123

10.1111/jgh.15133 | PMID 32511791 Get It

AbstractThe available COVID‐19 literature has focused on specific disease manifestations, infection control, and delivery or prioritization of services for specific patient groups in the setting of the acute COVID‐19 pandemic. Local health systems aim to contain the COVID‐19 pandemic and hospitals and health‐care providers rush to provide the capacity for a surge of COVID‐19 patients. However, the short, medium‐term, and long‐term outcomes of patients with gastrointestinal (GI) diseases without COVID‐19 will be affected by the ability to develop locally adapted strategies to meet their service needs in the COVID‐19 setting. To mitigate risks for patients with GI diseases, it is useful to differentiate three phases: (i) the acute phase, (ii) the adaptation phase, and (iii) the consolidation phase. During the acute phase, service delivery for patients with GI disease will be curtailed to meet competing health‐care needs of COVID‐19 patients. During the adaptation phase, GI services are calibrated towards a “new normal,” and the consolidation phase is characterized by rapid introduction and ongoing refinement of services. Proactive planning with engagement of relevant stakeholders including consumer representatives is required to be prepared for a variety of scenarios that are dictated by thus far undefined long‐term economic and societal impacts of the pandemic. Because substantial changes to the delivery of services are likely to occur, it is important that these changes are embedded into quality and research frameworks to ensure that data are generated that support evidence‐based decision‐making during the adaptation and consolidation phases.